- Design
- Retrospective cohort with propensity matching (EUSTAR)
- Population
- 614 patients with SSc and catheter-confirmed precapillary PH
- Primary outcome
- Mortality and PH worsening
- Effect
- Survival HR 0.98 (95% CI 0.72 to 1.33); PH worsening HR 1.07 (0.81 to 1.41)
The EUSTAR database identified 614 patients with systemic sclerosis and precapillary pulmonary hypertension confirmed by right heart catheterisation; 143 (23%) were on oral anticoagulation at diagnosis.
Anticoagulation was not associated with survival (HR 0.98, 95% CI 0.72 to 1.33) or with worsening pulmonary hypertension (HR 1.07, 0.81 to 1.41). Results held after propensity matching and in the 230 patients without interstitial lung disease. Anticoagulated patients had worse haemodynamics at baseline.
Earlier data have hinted at harm from anticoagulation in this group, largely from bleeding including gastrointestinal telangiectasia. This cohort shows no benefit to set against that risk. Anticoagulation should be for its own indications — atrial fibrillation, venous thromboembolism — not for the pulmonary hypertension.
- Do not start anticoagulation for SSc-associated pulmonary hypertension alone.
- Review patients already anticoagulated: is there another indication?
- Weigh gastrointestinal bleeding risk from telangiectasia and GAVE.
- Continue PAH-specific therapy through a pulmonary hypertension centre.
Why it matters
It removes a residual reason some clinicians still anticoagulate these patients.
Don't overread it
Observational; it shows no association, not proven absence of any effect in every subgroup.
The statistics, in plain English
A hazard ratio of 0.98 with an interval from 0.72 to 1.33 means no detectable effect either way. Confounding by indication — sicker patients receiving anticoagulation — could hide a small benefit or harm, but propensity matching did not change the result.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free